A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments

The epidermal growth factor receptor (EGFR) is a transmembrane protein that influences the pathogenesis in a subset of non-small cell lung cancers (NSCLC) [1]. Activation of EGFR is achieved by somatic mutations that lead to a ligand-independent activation of EGFR and uncontrolled cell growth [2,3]. Over the past decades, multiple tyrosine kinase inhibitors (TKIs) have been developed to inhibit growth of EGFR-mutated NSCLC. These drugs affect the intrinsic mitochondrial apoptotic pathway and thereby induce cell death [4].

Source: Cancer Treatment Reviews - September 19, 2023 Category: Cancer & Oncology Authors: Fenneke Zwierenga, Bianca A.M.H. van Veggel, Anke van den Berg, Harry J.M. Groen, Lili Zhang, Matthew R. Groves, K. Kok, E.F. Smit, T. Jeroen N. Hiltermann, Adrianus J. de Langen, Anthonie J. van der Wekken Tags: Anti-tumour Treatment Source Type: research